<- Go Home
TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Market Cap
$286.3K
Volume
144.0K
Cash and Equivalents
$1.0M
EBITDA
-$11.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$109.87
52 Week Low
$0.44
Dividend
N/A
Price / Book Value
0.13
Price / Earnings
-0.01
Price / Tangible Book Value
0.19
Enterprise Value
$935.4K
Enterprise Value / EBITDA
-0.08
Operating Income
-$11.9M
Return on Equity
577.04%
Return on Assets
-98.20
Cash and Short Term Investments
$1.0M
Debt
$1.7M
Equity
$2.0M
Revenue
N/A
Unlevered FCF
-$6.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium